Article: Symyx Signs ExxonMobil Deal: $200M For Fuel-Products Work.

National Editor

About two months after spinning off a therapeutics company based on its high-throughput technology, Symyx Technologies Inc. has entered a five-year deal worth at least $200 million to apply the same methods in research with fuel giant ExxonMobil.

Symyx's stock (NASDAQ:SMMX) closed Tuesday at $19.20, up $2.87, or 17.6 percent.

The deal "doesn't have anything whatsoever to do with that subsidiary working in the drug-discovery field," Steven Goldby, chairman and CEO of Santa Clara, Calif.-based Symyx, said during a conference call. Instead, it dramatically broadens a relationship already in place with ExxonMobil, of Irving, Texas.

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!